

## APPENDIX B

### VERSION WITH MARKINGS TO SHOW CHANGES MADE

37 C.F.R. § 1.121(b)(iii) AND (c)(ii)

#### CLAIMS:

3. The use according to [any preceding claim] claim 1, wherein the chemokine receptor antagonist is an amino-terminally truncated chemokine.
4. The use according to [claims 1 or 2] claim 1, wherein the chemokine receptor antagonist is an amino-terminally extended RANTES.
5. The use according to [claims 1 or 2] claim 1, wherein the chemokine receptor antagonist is Met-RANTES.
6. The use according to [any preceding claim] claim 1, wherein the cyclosporin is selected among cyclosporin A as well as metabolites or synthetic analogues thereof.
7. The use according to [any preceding claim] claim 1, wherein the cyclosporin is cyclosporin A.
8. The use according to [any preceding claim] claim 1, for treating or preventing renal allograft transplantation.
11. The pharmaceutical composition according to [claim 9 or 10] claim 9, wherein the chemokine receptor antagonist is an amino-terminally truncated chemokine.
12. The pharmaceutical composition according to [claims 9 or 10] claim 9, wherein the chemokine receptor antagonist is an amino-terminally extended RANTES.
13. The pharmaceutical composition according to [claims 9 or 10] claim 9, wherein the chemokine receptor antagonist is Met-RANTES.

14. The pharmaceutical composition according to [any of claims 9 to 13] claim 9, wherein the cyclosporin is selected among cyclosporin A as well as metabolites or synthetic analogues thereof.

15. The pharmaceutical composition according to [any of claims 10 to 14] claim 10, wherein the cyclosporin is cyclosporin A.

16. The pharmaceutical composition according to [any of claims 9 to 15] claim 9, for treating or preventing renal allograft transplantation.